Cingulate (CING) Non-Current Assets (2021 - 2026)
Cingulate's (CING) quarterly Non-Current Assets came in at $3.1 million in Q4 2025, up 39.09% YoY from $2.2 million in Q4 2024, and down 0.67% on a QoQ basis from $3.1 million in Q3 2025.
Cingulate (CING) Non-Current Assets (2021 - 2026) Analysis & Trends
Cingulate (CING) has 5 years of Non-Current Assets data on file, last reported at $3.1 million in Q4 2025.
- Quarterly Non-Current Assets rose 39.09% year-over-year to $3.1 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $10.3 million (up 5.09% YoY) and the FY2025 annual result came in at $3.1 million, up 39.09% from the prior year.
- Non-Current Assets eased to $3.1 million in Q4 2025, from $3.1 million in the prior quarter.
- In the past five years, Non-Current Assets ranged from a high of $4.0 million in Q4 2021 to a low of $2.0 million in Q1 2025.
- A 5-year average of $3.1 million and a median of $3.1 million in 2025 frame the typical range for Non-Current Assets.
- The widest YoY moves for Non-Current Assets: up 39.09% in 2025, down 29.02% in 2025.
- Tracing CING's Non-Current Assets over 5 years: stood at $4.0 million in 2021, then fell by 11.7% to $3.5 million in 2022, then retreated by 17.61% to $2.9 million in 2023, then dropped by 24.35% to $2.2 million in 2024, then surged by 39.09% to $3.1 million in 2025.
- The last three Non-Current Assets figures came in at $3.1 million (Q4 2025), $3.1 million (Q3 2025), and $2.0 million (Q1 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.96 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 5.15 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 1.96 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 938.60 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 6.80 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 468.65 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 18.06 Bn |
| 10 | Cingulate | 72.85 Mn | 72.85 Mn | - | 2.86 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.86 Mn |
| Dec 31, 2025 | 3.07 Mn |
| Sep 30, 2025 | 3.09 Mn |
| Mar 31, 2025 | 1.96 Mn |
| Dec 31, 2024 | 2.20 Mn |
| Sep 30, 2024 | 2.24 Mn |
| Jun 30, 2024 | 2.61 Mn |
| Mar 31, 2024 | 2.77 Mn |
| Dec 31, 2023 | 2.91 Mn |
| Sep 30, 2023 | 2.97 Mn |
| Jun 30, 2023 | 3.19 Mn |
| Mar 31, 2023 | 3.41 Mn |
| Dec 31, 2022 | 3.54 Mn |
| Sep 30, 2022 | 3.54 Mn |
| Jun 30, 2022 | 3.70 Mn |
| Mar 31, 2022 | 3.86 Mn |
| Dec 31, 2021 | 4.00 Mn |